Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement

Wilson Gonsalves, Francis K. Buadi, Sikander Ailawadhi, Peter Leif Bergsagel, Asher A Chanan Khan, David M Dingli, Angela Dispenzieri, Rafael Fonseca, Susan R. Hayman, Prashant Kapoor, Taxiarchis Kourelis, Martha Lacy, Jeremy T. Larsen, Eli Muchtar, Craig B. Reeder, Taimur Sher, Alexander Keith Stewart, Rahma Warsame, Ronald S. Go, Robert A. KyleNelson Leung, Yi Lin, John A. Lust, Stephen J Russell, Stephen R. Zeldenrust, Amie L. Fonder, Yi L. Hwa, Miriam A. Hobbs, Angela A. Mayo, William Hogan, S Vincent Rajkumar, Shaji K Kumar, Morie Gertz, Vivek Roy

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Over the last two decades, the utilization of various novel therapies in the upfront or salvage settings has continued to improve survival outcomes for patients with Multiple Myeloma (MM). Thus, the conventional role for hematopoietic stem cell transplantation (HSCT) in MM either in the form of an autologous stem cell transplant (ASCT) or an allogeneic stem cell transplant (Allo-SCT) warrants re-evaluation, given the aforementioned clinical advances. Here, we present a consensus statement of our multidisciplinary group of over 30 Mayo Clinic physicians with a special interest in the care of patients with MM and provide evidence-based recommendations on the use of HSCT in MM. We specifically address topics that include the role and timing of an ASCT for MM in the era of novel agents, eligibility for an ASCT, post-ASCT consolidation, and maintenance options, and finally the utility of an upfront tandem ASCT, salvage second ASCT, and an allo-SCT in MM.

Original languageEnglish (US)
Pages (from-to)1-15
Number of pages15
JournalBone Marrow Transplantation
DOIs
StateAccepted/In press - Jul 9 2018

Fingerprint

Hematopoietic Stem Cell Transplantation
Multiple Myeloma
Stem Cells
Transplants
Therapeutics
Patient Care
Maintenance
Physicians
Survival

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

@article{87423d36eb814d19ac81a60fdcb8e85e,
title = "Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement",
abstract = "Over the last two decades, the utilization of various novel therapies in the upfront or salvage settings has continued to improve survival outcomes for patients with Multiple Myeloma (MM). Thus, the conventional role for hematopoietic stem cell transplantation (HSCT) in MM either in the form of an autologous stem cell transplant (ASCT) or an allogeneic stem cell transplant (Allo-SCT) warrants re-evaluation, given the aforementioned clinical advances. Here, we present a consensus statement of our multidisciplinary group of over 30 Mayo Clinic physicians with a special interest in the care of patients with MM and provide evidence-based recommendations on the use of HSCT in MM. We specifically address topics that include the role and timing of an ASCT for MM in the era of novel agents, eligibility for an ASCT, post-ASCT consolidation, and maintenance options, and finally the utility of an upfront tandem ASCT, salvage second ASCT, and an allo-SCT in MM.",
author = "Wilson Gonsalves and Buadi, {Francis K.} and Sikander Ailawadhi and Bergsagel, {Peter Leif} and {Chanan Khan}, {Asher A} and Dingli, {David M} and Angela Dispenzieri and Rafael Fonseca and Hayman, {Susan R.} and Prashant Kapoor and Taxiarchis Kourelis and Martha Lacy and Larsen, {Jeremy T.} and Eli Muchtar and Reeder, {Craig B.} and Taimur Sher and Stewart, {Alexander Keith} and Rahma Warsame and Go, {Ronald S.} and Kyle, {Robert A.} and Nelson Leung and Yi Lin and Lust, {John A.} and Russell, {Stephen J} and Zeldenrust, {Stephen R.} and Fonder, {Amie L.} and Hwa, {Yi L.} and Hobbs, {Miriam A.} and Mayo, {Angela A.} and William Hogan and Rajkumar, {S Vincent} and Kumar, {Shaji K} and Morie Gertz and Vivek Roy",
year = "2018",
month = "7",
day = "9",
doi = "10.1038/s41409-018-0264-8",
language = "English (US)",
pages = "1--15",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma

T2 - a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement

AU - Gonsalves, Wilson

AU - Buadi, Francis K.

AU - Ailawadhi, Sikander

AU - Bergsagel, Peter Leif

AU - Chanan Khan, Asher A

AU - Dingli, David M

AU - Dispenzieri, Angela

AU - Fonseca, Rafael

AU - Hayman, Susan R.

AU - Kapoor, Prashant

AU - Kourelis, Taxiarchis

AU - Lacy, Martha

AU - Larsen, Jeremy T.

AU - Muchtar, Eli

AU - Reeder, Craig B.

AU - Sher, Taimur

AU - Stewart, Alexander Keith

AU - Warsame, Rahma

AU - Go, Ronald S.

AU - Kyle, Robert A.

AU - Leung, Nelson

AU - Lin, Yi

AU - Lust, John A.

AU - Russell, Stephen J

AU - Zeldenrust, Stephen R.

AU - Fonder, Amie L.

AU - Hwa, Yi L.

AU - Hobbs, Miriam A.

AU - Mayo, Angela A.

AU - Hogan, William

AU - Rajkumar, S Vincent

AU - Kumar, Shaji K

AU - Gertz, Morie

AU - Roy, Vivek

PY - 2018/7/9

Y1 - 2018/7/9

N2 - Over the last two decades, the utilization of various novel therapies in the upfront or salvage settings has continued to improve survival outcomes for patients with Multiple Myeloma (MM). Thus, the conventional role for hematopoietic stem cell transplantation (HSCT) in MM either in the form of an autologous stem cell transplant (ASCT) or an allogeneic stem cell transplant (Allo-SCT) warrants re-evaluation, given the aforementioned clinical advances. Here, we present a consensus statement of our multidisciplinary group of over 30 Mayo Clinic physicians with a special interest in the care of patients with MM and provide evidence-based recommendations on the use of HSCT in MM. We specifically address topics that include the role and timing of an ASCT for MM in the era of novel agents, eligibility for an ASCT, post-ASCT consolidation, and maintenance options, and finally the utility of an upfront tandem ASCT, salvage second ASCT, and an allo-SCT in MM.

AB - Over the last two decades, the utilization of various novel therapies in the upfront or salvage settings has continued to improve survival outcomes for patients with Multiple Myeloma (MM). Thus, the conventional role for hematopoietic stem cell transplantation (HSCT) in MM either in the form of an autologous stem cell transplant (ASCT) or an allogeneic stem cell transplant (Allo-SCT) warrants re-evaluation, given the aforementioned clinical advances. Here, we present a consensus statement of our multidisciplinary group of over 30 Mayo Clinic physicians with a special interest in the care of patients with MM and provide evidence-based recommendations on the use of HSCT in MM. We specifically address topics that include the role and timing of an ASCT for MM in the era of novel agents, eligibility for an ASCT, post-ASCT consolidation, and maintenance options, and finally the utility of an upfront tandem ASCT, salvage second ASCT, and an allo-SCT in MM.

UR - http://www.scopus.com/inward/record.url?scp=85049630770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049630770&partnerID=8YFLogxK

U2 - 10.1038/s41409-018-0264-8

DO - 10.1038/s41409-018-0264-8

M3 - Article

C2 - 29988062

AN - SCOPUS:85049630770

SP - 1

EP - 15

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

ER -